Winston Wong, PharmD, serves as a consultant/advisor to Omeza helping to navigate policy and payer relationships with Medicare, Medicaid, and private payers to maximize reimbursement across multiple diseases and wound types.

Dr. Wong served for nearly 17 years as Associate Vice President, Pharmacy Management for CareFirst BlueCross BlueShield, where he was responsible for the development, implementation, and administration of the prescription benefit, including the Medicare Part D prescription benefit. He was also instrumental in the development and implementation of a pharmacist driven MTM program that has been recognized by CMS and many national organizations. He was a member of the APhA STAT on Payment from 2003-2005, which formulated the basis for the white paper on the provision of MTM services.

Dr. Wong is currently President of the W-Squared Group, an organization committed to assisting healthcare innovators develop their value statements and launch their technology in the commercial marketplace and the government. The company’s disease state areas of expertise include oncology, immunologic disorders, retinal disorders, and dementia disorders.

Dr. Wong is also the Editor-In-Chief for the Journal of Clinical Pathways, a journal committed to providing high-quality educational and informational articles as well as presenting original health economic outcomes research data to audience interested in utilizing clinical pathways as a tool to move towards value-based care. Dr. Wong was named as one of the Top 100 Healthcare Leaders in 2018 and one of the Top 100 Healthcare Visionaries in 2020 by the International Forum on Advancement in Healthcare.

He earned is Pharm.D. from the University of the Pacific in Stockton, CA, and conducted his pharmacy residency at University of Nebraska in adult internal medicine.